The company will focus on advancing a program in hematological malignancies and plans to launch a registrational trial in 2026.

The firm is now offering combined ex vivo drug sensitivity and genomic testing to cancer patients outside the clinical trial setting.

The firm's stock tumbled on the news, dropping from $24.45 per share at market close Monday to $15.24 per share when the market opened Tuesday.

The firm is refocusing its resources on a KAT6A degrader for estrogen receptor-positive breast cancer and a previously undisclosed JAK2 Inhibitor.

NEW YORK – Azalea Therapeutics launched on Tuesday, having raised $82 million in seed and Series A financing to develop in vivo genetic medicines for cancer and autoimmune conditions using its ...

Based on strong preclinical data on HMPL-A251 in HER2-positive tumor cell lines, the firm wants to take the therapy into clinical trials by year end.

The start of the trial marks an expansion of the firm's oncology pipeline, and the firm hopes mRNA-2808 will be the first of many T-cell engagers in its portfolio.

The firm, which had planned to submit a BLA in 2026 for AMT-130, described the FDA's latest feedback as a "drastic change" and "unexpected." ...

The agency said the move could halve the time it takes for biosimilars to enter the market, drive competition, and reduce ...

The company's outlook for the rest of the year was rosier than in the previous quarter, when it announced a cost-cutting plan ...

The Midwest hospital system aims to embed genetic testing into everyday care for heart disease and discover new genetic risk ...

The hospital system is betting the move will give it better control over turnaround time and allow it to be more "nimble" in ...